GlassScriptPhysician profile
Carmen Ayers
NPI 1851832869
$3,103.68
in general payments reported to CMS, 2019-2025
21 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $841 · 2023: $1,021 · 2024: $637 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.71 |
| Education | $163.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.23 | 2021-2024 | |
| Astellas Pharma US INC | $359.28 | 2021-2025 | Veozah, Myrbetriq |
| Organon LLC | $321.74 | 2021-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $319.58 | 2021-2025 | |
| Exeltis, USA INC. | $312.66 | 2022-2025 | Slynd |
| Mayne Pharma Commercial LLC | $185.23 | 2022-2024 | |
| Hologic Sales and Service, LLC | $165.97 | 2021-2024 | Thinprep 2000 Processor, Aptima |
| Sumitomo Pharma America, INC. | $126.05 | 2023-2024 | Gemtesa, Myfembree |
| Exact Sciences Corporation | $117.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Millicent US INC | $114.21 | 2025 | Intrarosa, Femlyv |
| Pfizer INC. | $77.55 | 2021-2024 | |
| Axonics, INC. | $65.98 | 2024 | Axonics |
| Amgen INC. | $62.91 | 2022-2024 | Prolia, Evenity |
| Shield Therapeutics INC | $51.64 | 2023-2024 | Accrufer |
| Therapeuticsmd, INC. | $50.24 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $42.99 | 2023 | Myrisk |
| Myovant Sciences INC. | $38.96 | 2022 | |
| Sage Therapeutics, LLC | $36.91 | 2025 | Zurzuvae |
| Scynexis, INC. | $21.62 | 2022 | |
| Boston Scientific Corporation | $19.97 | 2025 | Axonics |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.70 | 2024 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.